ASCRS clinical advisory on intracameral moxifloxacin injection for infection prophylaxis.
Journal
Journal of cataract and refractive surgery
ISSN: 1873-4502
Titre abrégé: J Cataract Refract Surg
Pays: United States
ID NLM: 8604171
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
received:
01
03
2023
accepted:
05
06
2023
medline:
23
10
2023
pubmed:
9
6
2023
entrez:
8
6
2023
Statut:
ppublish
Résumé
Moxifloxacin solution is frequently injected at the conclusion of cataract surgery for endophthalmitis prophylaxis. 2 different concentrations are most commonly available in the United States for intracameral (IC) use: 0.5% (5 mg/mL) and 0.1% (1 mg/mL). The recommended volume to be injected is different for the 2 concentrations, and incorrect dosing can increase the risk of toxic anterior segment syndrome or endophthalmitis. In addition, the U.S. Food and Drug Administration recently published an alert regarding potential adverse events associated with intraocular compounded moxifloxacin. This clinical advisory reviews the optimal dosing of IC moxifloxacin based on current evidence.
Identifiants
pubmed: 37290753
doi: 10.1097/j.jcrs.0000000000001237
pii: 02158034-202310000-00011
doi:
Substances chimiques
Moxifloxacin
U188XYD42P
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1068-1070Informations de copyright
Copyright © 2023 Published by Wolters Kluwer on behalf of ASCRS and ESCRS.
Déclaration de conflit d'intérêts
Disclosures: W.G. Myers is a consultant and Medical Director at Leiters and a consultant and minority owner of Zion Therapeutics. None of the other authors has any relevant financial conflict of interests to report.
Références
Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-health-care-professionals-risks-associated-intraocular-use-compounded-moxifloxacin . Accessed June 14, 2023.
Miller KM, Oetting TA, Tweeten JP, Carter K, Lee BS, Lin S, Nanji AA, Shorstein NH, Musch DC; American Academy of Ophthalmology Preferred Practice Pattern Cataract/Anterior Segment Panel. Cataract in the adult eye preferred practice pattern. Ophthalmology 2022;129:P1–P126
Chang DF, Rhee DJ. Antibiotic prophylaxis of postoperative endophthalmitis following cataract surgery: results of the 2021 ASCRS member survey. J Cataract Refract Surg 2022;48:3–7
Chang DF, Braga Mele R, Mamalis N, Masket S, Miller KM, Nichamin LD, Packard RB, Packer M. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the 2007 ASCRS Member Survey. J Cataract Refract Surg 2007;33:1988–1989
Chang DF, Braga-Mele R, Henderson BA, Mamalis N, Vasavada A. Antibiotic prophylaxis of postoperative endophthalmitis following cataract surgery: results of the 2014 ASCRS Member Survey. J Cataract Refract Surg 2015;41:1300–1305
Melega MV, Alves M, Cavalcanti Lira RP, Da Silva IC, Ferreira BG, Filho HL, Chaves FR, Martini AA, Freire LM, Dos Reis R, Arieta CE. Safety and efficacy of intracameral moxifloxacin for prevention of post-cataract endophthalmitis: randomized controlled clinical trial. J Cataract Refract Surg 2019;45:343–350
Haripriya A, Chang DF, Ravindran RD. Endophthalmitis reduction with intracameral moxifloxacin in eyes with and without surgical complications: results from two-million consecutive cataract surgeries. J Cataract Refract Surg 2019;45:1226–1233
Herrinton LJ, Shorstein NH, Paschal JF, Liu L, Contreras R, Winthrop KL, Chang WJ, Melles RB, Fong DS. Comparative effectiveness of antibiotic prophylaxis in cataract surgery. Ophthalmology 2016;123:287–294
Espiritu CRG, Caparas VL, Bolinao JG. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J Cataract Refract Surg 2007;33:63–68
Bowen RC, Zhou AX, Bondalapati S, Lawyer TW, Snow KB, Evans PR, Bardsley T, McFarland M, Kliethermes M, Shi D, Mamalis CA, Greene T, Rudnisky CJ, Ambati BK. Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis. Br J Ophthalmol 2018;102:1268–1276
Rathi VM, Sharma S, Das T, Khanna RC. Endophthalmitis prophylaxis study. Report 1: intracameral cefuroxime and moxifloxacin prophylaxis for the prevention of postcataract endophthalmitis in rural India. Indian J Ophthalmol 2020;68:819–824
Kessel L, Flesner P, Andresen J, Erngaard D, Tendal B, Hjortdal J. Antibiotic prevention of postcataract endophthalmitis: a systematic review and meta-analysis. Acta Ophthalmol 2015;93:303–317
Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-598_Vigamox.cfm#:∼:text=Approval%20Date%3A%204%2F15%2F2003 . Accessed June 14, 2023.
Kowalski RP, Romanowski EG, Mah FS, Yates KA, Gordon YJ. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthalmol 2005;140:497–504
Arshinoff SA, Modabber M. Dose and administration of intracameral moxifloxacin for prophylaxis of postoperative endophthalmitis. J Cataract Refract Surg 2016;42:1730–1741
Matsuura K, Suto C, Akura J, Inoue Y. Comparison between intracameral moxifloxacin administration methods by assessing intraocular concentrations and drug kinetics. Graefes Arch Clin Exp Ophthalmol 2013;251:1955–1959
Shorstein NH, Gardner S. Injection volume and intracameral moxifloxacin dose. J Cataract Refract Surg 2019;45:1498–1502
Chang DF, Prajna NV, Szczotka-Flynn LB, Benetz BA, Lass JH, O’Brien RC, Menegay HJ, Gardner S, Shekar, Madhu MS, Rajendrababu S, Rhee DJ. Comparative corneal endothelial cell toxicity of differing intracameral moxifloxacin doses after phacoemulsification. J Cataract Refract Surg 2020;46:355–359
Available at: https://www.federalregister.gov/documents/2020/07/31/2020-16649/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal . Accessed June 14, 2023.
Amireskandari A, Bean A, Mauger T. Toxic anterior segment syndrome with intracameral moxifloxacin: case report and review of the literature. Case Rep Ophthal Med 2021;2021:1–6
Available at: https://go.usp.org/l/323321/2021-08-31/5kmjww/323321/16304645801icecobH/797_PHARMACEUTICAL_COMPOUNDING_STERILE_PREPARATIONS_POST_Revised.pdf . Accessed June 14, 2023.
Available at: https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisions/788_particulate_matter_in_injections.pdf . Accessed June 14, 2023.
United States Pharmacopeia. General Chapter, (789) Particulate Matter in Ophthalmic Solutions. USP-NF. Rockville, MD: United States Pharmacopeia; 2023. Available at: https://doi.org/10.31003/USPNF_M99587_01_01 . Accessed June 14, 2023.
Arshinoff SA, Felfeli T, Modabber M. Aqueous level abatement profiles of intracameral antibiotics: a comparative mathematical model of moxifloxacin, cefuroxime, and vancomycin with determination of relative efficacies. J Cataract Refract Surg 2019;45:1568–1574
Shorstein NH, Liu L, Carolan JA, Herrinton L. Endophthalmitis prophylaxis failures in patients injected with intracameral antibiotic during cataract surgery. Am J Ophthalmol 2021;227:166–172
Fong JW, Ahmad KT, Chacko JG, Phillips PH. Corneal decompensation following intrastromal hydration of corneal wounds with 0.5% moxifloxacin. JCRS Online Case Rep 2021;9:e00059